Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.
作者信息
Rodríguez Rodríguez Mario, Castro Quismondo Nerea, Zafra Torres Denis, Gil Alos Daniel, Ayala Rosa, Martinez-Lopez Joaquín
机构信息
Department of Hematology, Hospital Universitario "12 de Octubre", Madrid, Spain.
Hematological Malignancies Clinical Research Unit, CNIO, Madrid, Spain.
出版信息
Int J Lab Hematol. 2021 Aug;43(4):O152-O155. doi: 10.1111/ijlh.13476. Epub 2021 Jan 27.
Abstract
摘要
相似文献
1
Increased von Willebrand factor antigen and low ADAMTS13 activity are related to poor prognosis in covid-19 patients.血管性血友病因子抗原增加和ADAMTS13活性降低与新冠病毒肺炎患者的不良预后相关。
Int J Lab Hematol. 2021 Aug;43(4):O152-O155. doi: 10.1111/ijlh.13476. Epub 2021 Jan 27.
2
ADAMTS13 activity to von Willebrand factor antigen ratio predicts acute kidney injury in patients with COVID-19: Evidence of SARS-CoV-2 induced secondary thrombotic microangiopathy.ADAMTS13 活性与血管性血友病因子抗原比值预测 COVID-19 患者的急性肾损伤：SARS-CoV-2 诱导的继发性血栓性微血管病的证据。
Int J Lab Hematol. 2021 Jul;43 Suppl 1(Suppl 1):129-136. doi: 10.1111/ijlh.13415. Epub 2020 Dec 3.
3
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19.血管性血友病因子和 ADAMTS13 活性作为 COVID-19 患者临床严重程度的标志物。
J Thromb Thrombolysis. 2021 Aug;52(2):497-503. doi: 10.1007/s11239-021-02457-9. Epub 2021 Apr 17.
4
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.新冠病毒感染患者中的ADAMTS13-血管性血友病因子轴
J Thromb Haemost. 2021 Feb;19(2):513-521. doi: 10.1111/jth.15191. Epub 2020 Dec 18.
5
von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients.中重度新冠肺炎患者血管性血友病因子/凝血因子Ⅷ裂解酶轴与静脉血栓栓塞症
Br J Haematol. 2021 Mar;192(6):1097-1100. doi: 10.1111/bjh.17216. Epub 2020 Dec 24.
6
Obstetric outcomes in pregnant COVID-19 women: the imbalance of von Willebrand factor and ADAMTS13 axis.妊娠期 COVID-19 孕妇的产科结局：血管性血友病因子和 ADAMTS13 轴的失衡。
BMC Pregnancy Childbirth. 2022 Feb 21;22(1):142. doi: 10.1186/s12884-022-04405-8.
7
A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients.ADAMTS13轻度缺乏与COVID-19的严重程度相关：危重症和非危重症患者凝血指标的比较
Blood Coagul Fibrinolysis. 2021 Oct 1;32(7):458-467. doi: 10.1097/MBC.0000000000001068.
8
Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy.血管性血友病因子/ADAMTS13 失衡在 COVID-19 凝血功能障碍中的作用。
Am J Physiol Heart Circ Physiol. 2022 Jan 1;322(1):H87-H93. doi: 10.1152/ajpheart.00204.2021. Epub 2021 Dec 10.
9
Von Willebrand factor collagen-binding capacity predicts in-hospital mortality in COVID-19 patients: insight from VWF/ADAMTS13 ratio imbalance.血管性血友病因子胶原结合能力可预测新冠病毒肺炎患者的院内死亡率：基于血管性血友病因子/含凝血酶敏感蛋白基序的去整合素样金属蛋白酶13比例失衡的见解
Angiogenesis. 2021 Aug;24(3):407-411. doi: 10.1007/s10456-021-09789-3. Epub 2021 May 11.
10
Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.ADAMTS13和血管性血友病因子在感染新型冠状病毒的患者血栓栓塞事件中的作用。
Int J Lab Hematol. 2020 Oct;42(5):e211-e212. doi: 10.1111/ijlh.13244. Epub 2020 May 22.
引用本文的文献
1
Immunity and Coagulation in COVID-19.新型冠状病毒肺炎中的免疫与凝血。
Int J Mol Sci. 2024 Oct 19;25(20):11267. doi: 10.3390/ijms252011267.
2
Immune thrombotic thrombocytopenic purpura: pathogenesis and novel therapies: a narrative review.免疫性血栓性血小板减少性紫癜：发病机制与新疗法：一篇叙述性综述
Ann Blood. 2023 Sep 30;8. doi: 10.21037/aob-22-29. Epub 2023 Jan 6.
3
ADAMTS13 or Caplacizumab Reduces the Accumulation of Neutrophil Extracellular Traps and Thrombus in Whole Blood of COVID-19 Patients under Flow.ADAMTS13 或卡普立珠单抗减少 COVID-19 患者全血中中性粒细胞胞外诱捕网和血栓的形成。
Thromb Haemost. 2024 Aug;124(8):725-738. doi: 10.1055/a-2253-9359. Epub 2024 Jan 25.
4
Dynamic Assessment of Plasma von Willebrand Factor and ADAMTS13 Predicts Mortality in Hospitalized Patients with SARS-CoV-2 Infection.血浆血管性血友病因子和含血小板解聚蛋白及金属蛋白酶13的动态评估可预测新型冠状病毒肺炎住院患者的死亡率
J Clin Med. 2023 Nov 19;12(22):7174. doi: 10.3390/jcm12227174.
5
Von Willebrand factor and the thrombophilia of severe COVID-19: evidence from autopsies.血管性血友病因子与重症新型冠状病毒肺炎的血栓形成倾向：尸检证据
Res Pract Thromb Haemost. 2023 May;7(4):100182. doi: 10.1016/j.rpth.2023.100182. Epub 2023 May 18.
6
Status of major hemostatic components in the setting of COVID-19: the effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement.新型冠状病毒肺炎背景下主要止血成分的状态：对血管内皮、血小板、凝血因子、纤维蛋白溶解系统和补体的影响。
Ann Hematol. 2023 Jun;102(6):1307-1322. doi: 10.1007/s00277-023-05234-1. Epub 2023 Apr 19.
7
A novel mechanism underlying allosteric regulation of ADAMTS-13 revealed by hydrogen-deuterium exchange plus mass spectrometry.氢氘交换质谱法揭示的ADAMTS-13变构调节潜在新机制
Res Pract Thromb Haemost. 2022 Dec 13;7(1):100012. doi: 10.1016/j.rpth.2022.100012. eCollection 2023 Jan.
8
Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19.恢复期血浆输注对重症和危重症新型冠状病毒肺炎患者中ADAMTS13-血管性血友病因子轴及内皮完整性的影响
Res Pract Thromb Haemost. 2023 Jan;7(1):100010. doi: 10.1016/j.rpth.2022.100010. Epub 2022 Dec 13.
9
An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection.血管紧张素转换酶2的结构/功能、多态性及其在2019冠状病毒病病理生理学中的双重性质的最新进展：对与严重急性呼吸综合征冠状病毒感染相关的血管和凝血疾病的影响。
Front Microbiol. 2022 Nov 28;13:1042200. doi: 10.3389/fmicb.2022.1042200. eCollection 2022.
10
Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.COVID-19 患者血管性血友病因子和 ADAMTS13 的预后价值：系统评价和荟萃分析。
Thromb Res. 2022 Oct;218:83-98. doi: 10.1016/j.thromres.2022.08.017. Epub 2022 Aug 18.
本文引用的文献
1
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.新冠肺炎患者的血栓前状态改变与疾病严重程度和死亡率相关。
Res Pract Thromb Haemost. 2020 Dec 6;5(1):132-141. doi: 10.1002/rth2.12462. eCollection 2021 Jan.
2
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.新冠病毒感染患者中的ADAMTS13-血管性血友病因子轴
J Thromb Haemost. 2021 Feb;19(2):513-521. doi: 10.1111/jth.15191. Epub 2020 Dec 18.
3
Reduction of ADAMTS13 Levels Predicts Mortality in SARS-CoV-2 Patients.ADAMTS13水平降低可预测新冠病毒患者的死亡率。
TH Open. 2020 Aug 30;4(3):e203-e206. doi: 10.1055/s-0040-1716379. eCollection 2020 Jul.
4
A comprehensive assessment of the coagulation profile in critically ill COVID-19 patients.对危重症COVID-19患者凝血状况的全面评估。
Thromb Res. 2020 Oct;194:42-44. doi: 10.1016/j.thromres.2020.06.026. Epub 2020 Jun 18.
5
A relative ADAMTS13 deficiency supports the presence of a secondary microangiopathy in COVID 19.ADAMTS13相对缺乏支持新冠病毒感染中继发性微血管病的存在。
Thromb Res. 2020 Sep;193:170-172. doi: 10.1016/j.thromres.2020.07.034. Epub 2020 Jul 18.
6
Vasculopathy and Coagulopathy Associated with SARS-CoV-2 Infection.与 SARS-CoV-2 感染相关的血管病变和凝血病。
Cells. 2020 Jun 30;9(7):1583. doi: 10.3390/cells9071583.
7
Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients.低ADAMTS 13血浆水平是COVID-19患者死亡率的预测指标。
Intern Emerg Med. 2020 Aug;15(5):861-863. doi: 10.1007/s11739-020-02394-0. Epub 2020 Jun 18.
8
ADAMTS13 activity, von Willebrand factor, factor VIII and D-dimers in COVID-19 inpatients.新冠住院患者的ADAMTS13活性、血管性血友病因子、凝血因子VIII及D-二聚体
Thromb Res. 2020 Aug;192:174-175. doi: 10.1016/j.thromres.2020.05.032. Epub 2020 May 23.
9
COVID-19 coagulopathy: an evolving story.新冠病毒感染相关凝血功能障碍：一个不断演变的故事。
Lancet Haematol. 2020 Jun;7(6):e425. doi: 10.1016/S2352-3026(20)30151-4.
10
Involvement of ADAMTS13 and von Willebrand factor in thromboembolic events in patients infected with SARS-CoV-2.ADAMTS13和血管性血友病因子在感染新型冠状病毒的患者血栓栓塞事件中的作用。
Int J Lab Hematol. 2020 Oct;42(5):e211-e212. doi: 10.1111/ijlh.13244. Epub 2020 May 22.
Zotero 插件